CD274 and neoplasm: Immune checkpoint inhibitors (ICIs), especially antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), provided a new paradigm against cancer and were considered as promising anti-tumor treatments in NSCLC (7–10).